NeoGenomics (NEO) Completes Acquisition of Pathline

NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced it has completed its previously announced acquisition of Pathline, LLC, a CLIA/CAP/NYS-certified laboratory based in New Jersey.

With the acquisition, NeoGenomics strengthens its commercial presence in the Northeast U.S. and broadens access to its comprehensive oncology test menu, expands its service capabilities, and accelerates growth in molecular and hematology-oncology testing.

You May Also Be Interested In

• Microchip releases free VectorBlox 3.0 SDK for FPGA-based AI
• Youxin Technology signs non-binding $20M investment deal with RiverBit
• Dream Finders Homes names ex-Lennar CEO Rick Beckwitt as co-chairman